Willem W. van Weperen
Keine laufenden Positionen mehr
Profil
Willem W.
van Weperen formerly worked at to-BBB Holding BV, as Chief Executive Officer, to-BBB technologies BV, as Chief Executive Officer, Amicus Therapeutics, Inc., as Regional Vice President from 2015 to 2020, Prosensa Holding NV, as Chief Commercial Officer, Naarden Agro Products BV, as Principal, Glaxo, Inc., as Clinical Researcher, and Genzyme Europe BV, as General Manager.
Mr. van Weperen received his graduate degree from the University of Utrecht and Masters Business Admin degree from Nimbas Bradford School of Management.
Ehemalige bekannte Positionen von Willem W. van Weperen
Unternehmen | Position | Ende |
---|---|---|
AMICUS THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2020 |
PROSENSA HOLDING NV | Corporate Officer/Principal | - |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Corporate Officer/Principal | - |
Naarden Agro Products BV
Naarden Agro Products BV Food: Meat/Fish/DairyConsumer Non-Durables Naarden Agro Products BV engages in processing and selling caseins. It offers skimmed milk powder, full-cream milk powder, sweet whey powder, milk protein concentrates, whey protein concentrates and industrial lactic acid caseins. The company is headquartered in Nijkerk, the Netherlands. | Corporate Officer/Principal | - |
to-BBB Holding BV
to-BBB Holding BV Pharmaceuticals: GenericHealth Technology to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands. | Vorstandsvorsitzender | - |
Ausbildung von Willem W. van Weperen
University of Utrecht | Graduate Degree |
Nimbas Bradford School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AMICUS THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
to-BBB technologies BV
to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
Glaxo, Inc. | |
to-BBB Holding BV
to-BBB Holding BV Pharmaceuticals: GenericHealth Technology to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands. | Health Technology |
Naarden Agro Products BV
Naarden Agro Products BV Food: Meat/Fish/DairyConsumer Non-Durables Naarden Agro Products BV engages in processing and selling caseins. It offers skimmed milk powder, full-cream milk powder, sweet whey powder, milk protein concentrates, whey protein concentrates and industrial lactic acid caseins. The company is headquartered in Nijkerk, the Netherlands. | Consumer Non-Durables |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Health Technology |
Prosensa Holding NV
Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |